Notícias ARS Pharmaceuticals Inc - SPRY | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc (SPRY) Notícias

ARS Pharmaceuticals Inc (SPRY)

14,00

0,62

(4,63%)

Fechado 25 Novembro 6:00PM

Atrasado por 15 minutos

13,64

-0,36

(-2,57%)

Após o horário de negociação: 9:15PM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

ARS Pharmaceuticals

Amundi Index MSCI North ...

Amundi MSCI US ESG LEAD ...

IOCHP-MAXION ON

Canadian Net Real Estate... (PK)

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições